UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/549,824	09/20/2005	Ying Wu	65959/53	3692
7590 01/31/2007 Craig J Arnold Amster Rothstein & Ebenstein 90 Park Avenue New York, NY 10016			EXAMINER	
			JUNG, UNSU	
			ART UNIT	PAPER NUMBER
			1641	
SHORTENED STATUTO	RY PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE	
31 DAVS		01/31/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

	Application No.	Applicant(s)				
	10/549,824	WU ET AL.				
Office Action Summary	Examiner	Art Unit				
	Unsu Jung	1641				
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address				
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DATE of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period of Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be timulated and will expire SIX (6) MONTHS from a cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).				
Status						
1)⊠ Responsive to communication(s) filed on 20 S	eptember 2005.	•				
	· _ ·					
,—	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims						
4)⊠ Claim(s) <u>1-24</u> is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6) Claim(s) is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) 1-24 are subject to restriction and/or election requirement.						
Application Papers	,					
9) The specification is objected to by the Examiner.						
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119						
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail D 5) Notice of Informal F 6) Other:	ate				

Art Unit: 1641

DETAILED ACTION

1.. Applicants' amendments to claims 3, 4, 6-12, 14, 16, 17, 19, 20, and 22-24 in the reply filed on September 20, 2005 have been acknowledged and entered.

2. Claims 1-24 are pending.

Election/Restrictions

3. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-22 and 24, drawn to a method of providing biomolecules on a metal oxide substrate, a metal oxide substrate, and a kit comprising a metal oxide substrate.

Group II, claim(s) 12-24, drawn to a method for performing probe-based assays using a metal oxide substrate, a metal oxide substrate, and a kit comprising a metal oxide substrate.

The inventions listed as Groups I and II do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the special technical feature of Groups I and II is the metal oxide substrate. The metal oxide substrate cannot be a special technical feature under PTC Rule 13.2 because the metal oxide substrate has been shown in the prior art. Rupp et al. (U.S. PG Pub. No. US 2004/0014061 A2, Published as a WO 01/85989 on Nov. 15, 2001) teaches the metal oxide substrate having a surface that is coated with a polymer and having biomolecules immobilized on the substrate (pp3-4, paragraph [0028]).

Art Unit: 1641

Election of Species within Group I

4. This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

The species are as follows:

List I: Polymer

- A. Poly-aspartate
- B. Poly-glutamate
- C. Poly-cystein
- D. Poly-serine
- E. Poly-methionine
- F. Poly-arginine
- G. Poly-histidine
- H. Poly-tryptophane
- 1. Poly-alanine
- J. Poly-lysine
- K. Poly-leucine
- L. Poly-isoleucine
- M. Poly-tyrosine
- N. Poly-valine
- O. Poly-glycine
- P. Poly-proline
- Q. Poly-phenylalanine
- R. Poly-threonine
- S. Polymers of natural amino acids
- T. Polymers of non-natural amino acids
- U. Derivatives thereof
- V. Mixtures theréof

List II: Biomolecules

- A. Oligonucleotides
- B. Polynucleotides
- C. Ribonucleotides
- D. Proteins
- E. Antibodies
- F. Antigens
- G. Peptides
- H. Oligo or poly-saccharides

Art Unit: 1641

- I. Receptors
- J. Haptens
- K. Ligands
- L. Drugs
- M. Toxins
- N. Liposomes

List III: Labels

- A. Bioluminescence
- B. Chemiluminescence
- C. Photoluminescence

Applicant is required, in reply to this action, to elect a single species from three lists of species to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

The claims are deemed to correspond to the species listed above in the following manner:

List I: Polymer

- A. Poly-aspartate (claim 4)
- B. Poly-glutamate (claim 4)
- C. Poly-cystein (claim 4)
- D. Poly-serine (claim 4)
- E. Poly-methionine (claim 4)
- F. Poly-arginine (claim 4)
- G. Poly-histidine (claim 4)
- H. Poly-tryptophane (claim 4)

Art Unit: 1641

- I. Poly-alanine (claim 4)
- J. Poly-lysine (claims 4, 5, 15, and 18)
- K. Poly-leucine (claim 4)
- L. Poly-isoleucine (claim 4)
- M. Poly-tyrosine (claim 4)
- N. Poly-valine (claim 4)
- O. Poly-glycine (claim 4)
- P. Poly-proline (claim 4)
- Q. Poly-phenylalanine (claim 4)
- R. Poly-threonine (claim 4)
- S. Polymers of natural amino acids (claim 4)
- T. Polymers of non-natural amino acids (claim 4)
- U. Derivatives thereof (claim 4)
- V. Mixtures thereof (claim 4)

List II: Biomolecules

- A. Oligonucleotides (claim 11)
- B. Polynucleotides (claim 11)
- C. Ribonucleotides (claim 11)
- D. Proteins (claim 11)
- E. Antibodies (claim 11)
- F. Antigens (claim 11)
- G. Peptides (claim 11)
- H. Oligo or poly-saccharides (claim 11)
- I. Receptors (claim 11)
- J. Haptens (claim 11)
- K. Ligands (claim 11)
- L. Drugs (claim 11)
- M. Toxins (claim 11)
- N. Liposomes (claim 11)

List III: Labels

- A. Bioluminescence (claim 22)
- B. Chemiluminescence (claim 22)
- C. Photoluminescence (claim 22)

The following claim(s) are generic: claims 1-3, 6-10, 12-14, 16, 17, 19-21, and 24.

The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: each species of polymer, biomolecules, and labels have different special technical features as each species of polymer, biomolecules, and labels include structurally and molecularly distinct species

Art Unit: 1641

of compounds. Therefore, each species of polymer, biomolecules, and labels lack unity

of invention.

Election of Species within Group II

5. This application contains claims directed to more than one species of the generic

invention. These species are deemed to lack unity of invention because they are not so

linked as to form a single general inventive concept under PCT Rule 13.1.

The species are as follows:

List: Labels

A. Bioluminescence

B. Chemiluminescence

C. Photoluminescence

Applicant is required, in reply to this action, to elect a single species from three

lists of species to which the claims shall be restricted if no generic claim is finally held to

be allowable. The reply must also identify the claims readable on the elected species,

including any claims subsequently added. An argument that a claim is allowable or that

all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration

of claims to additional species which are written in dependent form or otherwise include

all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims

are added after the election, applicant must indicate which are readable upon the

elected species. MPEP § 809.02(a).

The claims are deemed to correspond to the species listed above in the following

manner:

Application/Control Number: 10/549,824

Page 7

Art Unit: 1641

List: Labels

A. Bioluminescence (claim 22)

- B. Chemiluminescence (claim 22)
- C. Photoluminescence (claim 22)

The following claim(s) are generic: claims 1-3, 6-10, 12-14, 16, 17, 19-21, and 24.

The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: each species of labels have different special technical features as each species of labels include structurally and molecularly distinct species of compounds capable of producing different types of luminescence (bio, chemi, and photoluminescence). Therefore, each species of labels lack unity of invention.

6. Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Application/Control Number: 10/549,824

Art Unit: 1641

- 7. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).
- 8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Unsu Jung whose telephone number is 571-272-8506. The examiner can normally be reached on M-F: 9-5.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Long Le can be reached on 571-272-0823. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Page 9

Unsu Jung, Ph.D. Patent Examiner

Art Unit 1641

LONG V. LE 01/20/07
SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600